SEARCH

SEARCH BY CITATION

References

  • Anderson GD. (2002) Phenobarbital – chemistry and pharmacokinetics and biotransformation. In Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia, pp. 496503.
  • Anderson GD, Levy RH. (1995) Phenobarbital – chemistry and pharmacokinetics and biotransformation. In Levy RH, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 371378.
  • Backonja MM, Canafax DM, Cundy KC. (2011) Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison. Pain Med12:10981108.
  • Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Poderbeazsky A, Agam G, Belmaker RH. (2010) Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial. Bipolar Disord12:376382.
  • Bialer M. (1991) Clinical pharmacology of valpromide. Clin Pharmacokinet20:114122.
  • Bialer M. (2002) Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs. 5th ed. Lippincott, Philadelphia, PA, pp. 459465.
  • Bialer M. (2006) New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drug15:637647.
  • Bialer M. (2009) Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. Epilepsia50(Suppl. 12):4448.
  • Bialer M. (2012) Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev64:887895.
  • Bialer M, Soares-da-Silva P. (2012) Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia53:935946.
  • Bialer M, White HS. (2010) Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov9:6882.
  • Bialer M, Yagen B. (2007) Valproic acid – second generation. Neurotherapeutics4:130137.
  • Bialer M, Twyman RE, White HS. (2004) Correlation analysis between nariconvulsnat-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav5:866872.
  • Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. (2009) Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res83:143.
  • Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. (2010) Progress report on new antiepileptic drugs: a summary of the tenth Eilat Conference (EILAT X). Epilepsy Res92:89124.
  • Blitz H. (1908) Uber die Kpstitution der Einwirkugsproduckte von substituierten Harnstoffen uaf Benzyl under uber eingige neue Methoden zurDarstellung der 5,5-Diphenylhydantoine. Ber Dtsch Chem Ges41:1379.
  • Blum E. (1932) Diebekampfung epileptischer Anfalle und uhrer Forger scheinungen mit Prominal. Dtsch Med Wochenschr58:230236.
  • Bogue JY, Carrington HC. (1953) The evaluation of Mysoline – a new anticonvulsant drug. Br J Pharmacol8:230235.
  • Bourgeois BFD. (1995) Primidone – chemistry and biotransformation. In Levy RH, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 449457.
  • Bourgeois BFD, Dodson WE, Ferrendelli JA. (1983a) Primidone, phenobarbital and PEMA I. Seizure protection, neurotoxicity and therapeutic index of varying combinations in mice. Neurology33:283290.
  • Bourgeois BFD, Dodson WE, Ferrendelli JA. (1983b) Primidone, phenobarbital and PEMA II. Seizure protection, neurotoxicity and therapeutic index of varying combinations in mice. Neurology33:291295.
  • Browne TR, Evans JE, Szabo GK, Evans BA, Greenblatt DJ. (1985) Studies with stable isotopes II: phenobarbital pharmacokinetics during monotherapy. J Clin Pharmacol25:5158.
  • Burton BS. (1882) On the propyl derivatives and decomposition of ethylaceto-acetate. Am Chem J3:385395.
  • Buttler TC, Waddell WJ. (1956) Metblic conversion of primidone (Mysoline) to phenobarbital. Proc Soc Exp Biol Med93:544566.
  • Carraz G, Darbon M, Lebreton S, Beiriel H. (1964) Properties pharmamcodynamiques de l’acide n-dipropylacetique et ses derives. Therapy19:468476.
  • Clein NW. (1945) New antiepileptic in the treatment of epilepsy (3-methyl-5,5-phenyl-hydantoin) (Hydantal) Preliminary report. Northwest Med44:210212.
  • Cohen WAT. (1943) Cemisch-Historische Aanteel keningen. De nomenclatuur vas enkele organische zuren. Chem Weekbl40:176.
  • Cozanitis DA. (2004) One hundred years of barbiturates and their saint. J R Soc Med97:594598.
  • Dundee JW, Mellroy PDA. (1982) The history of barbiturates. Anesthesia37:726734.
  • Eadie MJ, Hooper WD. (1995) Phenobarbital – chemistry and other barbiturates. In Levy RH, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 421437.
  • Eadie MJ, Hooper WD. (2002) Phenobarbital – chemistry and other barbiturates. In Levy RH, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs. 5th ed. Lippincott, Philadelphia, PA, pp. 541548.
  • Enna SJ, Williams M. (2009) Challenges in the search for drugs to treat central nerve systems disorders. J Pharmacol Exp Ther32:401411.
  • Ferrendelli JA, Kupferberg HJ. (1980) Succinimides. In Glaser GH, Penry JK, Woodbury DM, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs: mechanisms of action. Raven Press, New York, pp. 587596.
  • Fieser LF. (1944) Organic chemistry. DC Healthy adn Compaany, Boston, MA, pp. 247.
  • Fischer E, von Mering J. (1903) Ueber eine neue Klasse von Schlafmittels. Ther Ggw44:97101.
  • Gallagher BB. (1986) Eterobarb. In Meldrum BS, Porter RJ (Eds) New anticonvulsant drugs. 4th ed. John Libby, London, pp. 103115.
  • Grosser T, Smyth E, FitzGerald GA. (2011) Anti-inflammatory, antipyretic and analgesic agents; pharmacotherapy of gout. In Brunton LL, Chabner BA, Knollmann BC (Eds) Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. McGraw Hill Medical, New York, pp. 9591004.
  • Hauptmann A. (1912) Luminal bei epilepsie. MMW Munch Med Wochenschr5:19071909.
  • Hooper WD, Qing MS. (1990) The influence of age and gender on the stereoselective metabolism and pharmacokinetics of methylphenobarbitone in humans. Clin Pharmacol Ther48:633640.
  • Jamerson B. (1994) Venous irritation related to intravenous administration of fosphenytoin versus Fosphenytoin. Pharmacotherapy1:4752.
  • Kupfer A, Brilis GM, Watson JT, Harris TM. (1980) A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation p-hydroxymephenytoin. Drug Metab Dispos8:14.
  • Kupfer A, Robaers RK, Schenker S, Branch RA. (1981) Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther218:193199.
  • Kupferberg HJ. (1995) Other hydantions – mephenytoin and ethotoin. In Levy RH, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 351357.
  • Kutt H. (1978) Clinical pharmacology of carbamazepine. In Pippinger CE, Penry JK, Kutt H (Eds) Antiepileptic drugs: quantitative analysis and interpretation. Raven Press, New York, pp. 297305.
  • Kwan P, Broide MJ. (2004) Phenobarbital for the treatment of epilepsy in 21st century: a critical review. Epilepsia45:11411149.
  • Leppik IE, Boucher BA, Wilder BJ, Murth VS, Watridge C, Graves NM, Rangel RJ, Rask CA, Turlapaty P. (1990) Pharmacokinetics and safety of phenytoin prodrug given IV in patients. Neurology40:456460.
  • Lim H, Hooper WD. (1989) Stereoselective metabolism and pharmacokinetics of methylphenobarbitone in humans. Drug Metab Disposit17:212217.
  • Loescher W. (1999) The discovery of valproate. In Loscher W (Ed.) Valproate. Birkhausee Verlag, Basel, pp. 13.
  • Lopez-Munos F, Ucha-Udabe R, Alamo C. (2005) The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat1:329343.
  • Mackey C. (2010) The anticonvulsants market. Nat Rev Drug Discov9:265266.
  • McElvian SM. (1935) 5,5-dipehnylbarbituric acid. J Am Chem Soc57:13031304.
  • Merritt HH, Putnam TJ. (1938) Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA111:10681073.
  • Meunier H, Carraz G, Meunier Y, Eymard P, Airmad M. (1963) Properties pharamcodynamiques de l’acide n-dipropylacetique. Ler memoire Proprietes antiepileptique. Therapy18:435438.
  • Mihic SJ, Haris RA. (2011) Hypnotics and sedatives. In Brunton LL, Chabner BA, Knollmann BC (Eds) Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. McGraw Hill Medical, New York, pp. 469475.
  • Miller CA, Long LM. (1953) Anticonvulsants IV. An investigation of a-α-(substituted phenyl) succinimides. J Am Chem Soc75:65366538.
  • Nalivaeva NN, Belyaev NCD, Turner JA. (2009) Sodium valproate: an old drug with new roles. THIPS30:509514.
  • Perucca E, French J, Bialer M. (2007) Developing novel antiepileptic drugs (AEDs): challenges, incentives and recent advances. Lancet Neurol6:793804.
  • Porter RJ. (1986) Antiepileptic drugs: efficacy and inadequacy. In Meldrum BS, Porter RJ (Eds) New anticonvulsant drugs. 4th ed. John Libby, London, pp. 315.
  • Prichard JW. (1980) Phenobarbital: introduction. In Glaser GH, Penry JK, Woodbury DM (Eds) Antiepileptic drugs, mechanism of action. Raven Press, New York, pp. 473491.
  • Pryor FM, Ramsay RE. (2002) Fosphenytoin. In Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs. 5th ed. Lippincott, Philadelphia, PA, pp. 611618.
  • Raines A, Niner JM, Pacer DG. (1973) A comparison of the anticonvulsant, neurotoxic and lethal effects of diphenylbarbituric acid, phenobarbital and diphenylhydantoin in the mouse. J Pharmacol Exp Ther186:315322.
  • Raines A, Baumel I, Gallagher BB, Niner JM. (1975) The effects of 5,5-diphenylbarbituric acid on experimental seizures in rats: correlation between plasma and brain concentration s and anticonvulsant activity. Epilepsia16:575581.
  • Roszkowski AP, Govier WM. (1962) Behavioral and central muscle relaxant properties of 2-ethyl-3-methlyvaleramide. Int J Neuropharmacol1:423430.
  • Sandberg F. (1951) A comparative study of the anticonvulsant effect of the N-substituted 5,5-diallylbarbiturates and 5,5-diphenylhydantoins. Acta Physiol Scand24:149162.
  • Sharpless SK. (1970) The barbiturates. In Goodman LS, Gilman A (Eds) Goodman & Gilman’s the pharmacological basis of therapeutics. 4th ed. McGraw Hill Medical, New York, pp. 98102.
  • Sherwin AL. (1978) Clinical pharmacology of ethosuximide. In Pippinger CE, Penry JK, Kutt H (Eds) Antiepileptic drugs: quantitative analysis and interpretation. Raven Press, New York, pp. 283295.
  • Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. (2007) Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J Med Chem50:64196427.
  • Shorter E. (1997) A history of psychiatry. From the era of the asylum to the age of parzac. J. Wiley, New York.
  • Sneader W. (1985) Drug discovery: the evolution of modern medicines. J. Wiley, Chichester.
  • Suria A, King Killam EHJ. (1980) Carbamazepine. In Glaser GH, Penry JK, Woodbury DM, Mattson RH, Meldrum BS (Eds) Antiepileptic drugs: mechanisms of action. Raven Press, New York, pp. 563575.
  • Vida JA, Gerry EH. (1977) Cyclic ureides. In Vida JA (Ed.) Anticonvulsants. Academic Press, New York, pp. 151173.
  • Wolter KD. (1991) Eterobarb. In Pisani F, Perucca E, Avanzini G, Richens A (Eds) New antiepileptic drugs, Epilepsy Res. Suppl. 3, Elsevier, Amsterdam, pp. 99102.